Clinical Study
The Incidence and Predictors of Thromboembolic Events in Patients with Lung Cancer
Table 3
Relationship between potential predictors and occurrence of thromboembolic events.
| | Any VTE | OR (95% CI)1 | Serious VTE | OR (95% CI)1 |
| | Sex () | | | | | | Male | 50 (8.3%) | Reference | 43 (7.2%) | Reference | | Female | 41 (11.7%) | 1.46 (0.94–2.26) | 37 (10.6%) | 1.53 (0.97–2.43) |
| | Age | | 1.02 (1.00–1.04)* | | 1.02 (1.00–1.04)* | | Age categorized () | | | | | | <50 | 11 (7.2%) | Reference | 10 (6.5%) | Reference | | 50–65 | 30 (8.4%) | 1.19 (0.58–2.44) | 24 (6.7%) | 1.03 (0.48–2.22) | | 65–80 | 34 (10.4%) | 1.50 (0.74–3.04) | 31 (9.5%) | 1.50 (0.71–3.14) | | >80 | 16 (14.0%) | 2.11 (0.94–4.74) | 15 (13.2%) | 2.17 (0.94–5.02) |
| | Histology () | | | | | | Adenocarcinoma | 37 (16.4%) | 3.79 (1.13–12.73)* | 32 (14.2%) | 3.19 (0.94–10.79) | | Squamous cell carcinoma | 19 (7.3%) | 1.52 (0.43–5.30) | 18 (6.9%) | 1.43 (0.41–5.03) | | Small cell carcinoma | 14 (8.0%) | 1.68 (0.47–6.06) | 11 (6.3%) | 1.30 (0.35–4.81) | | Large cell carcinoma | 3 (4.9%) | Reference | 3 (4.9%) | Reference | | NSCLC NOS | 9 (8.0%) | 1.67 (0.44–6.43) | 8 (7.1%) | 1.47 (0.38–5.77) | | Other | 6 (7.5%) | 1.57 (0.38–6.54) | 5 (6.3%) | 1.29 (0.30–5.62) | | Not determined | 3 (8.8%) | 1.87 (0.36–9.83) | 3 (8.8%) | 1.87 (0.36–9.83) |
| | Clinical stage () | | | | | | I | 9 (11.3%) | Reference | 7 (8.8%) | Reference | | II | 11 (14.5%) | 1.34 (0.52–3.43) | 10 (13.2%) | 1.58 (0.57–4.39) | | III | 29 (10.6%) | 0.93 (0.42–2.06) | 25 (9.1%) | 1.05 (0.44–2.52) | | IV | 36 (9.2%) | 0.80 (0.37–1.72) | 32 (8.1%) | 0.92 (0.39–2.18) |
| | Initial treatment () | | | | | | Chemotherapy | 44 (7.3%) | Reference | 39 (6.4%) | Reference | | Radiotherapy | 10 (22.2%) | 3.64 (1.69–7.84)* | 9 (20.0%) | 3.63 (1.63–8.07)* | | Surgery | 16 (10.7%) | 1.53 (0.84–2.80) | 13 (8.7%) | 1.39 (0.72–2.67) | | Targeted therapy | 3 (12.0%) | 1.74 (0.50–6.04) | 2 (8.0%) | 1.26 (0.29–5.55) | | Symptomatic treatment | 18 (9.6%) | 2.13 (1.18–3.82)* | 17 (13.5%) | 2.26 (1.24–4.15)* |
| | Smoking () | 81 (10.1%) | 1.11 (0.56–2.20) | 71 (8.9%) | 1.07 (0.52–2.21) | | COPD () | 44 (12.1%) | 1.59 (1.03–2.45)* | 39 (10.7%) | 1.60 (1.01–2.54)* | | Diabetes mellitus () | 27 (14.7%) | 1.89 (1.17–3.05)* | 25 (13.6%) | 2.03 (1.23–3.36)* | | Cerebrovascular disease () | 20 (22.0%) | 3.13 (1.80–5.43)* | 18 (19.8%) | 3.17 (1.78–5.64)* | | Hypertension () | 54 (14.4%) | 2.43 (1.57–3.78)* | 49 (13.0%) | 2.63 (1.64–4.20)* | | Hearth failure () | 32 (43.8%) | 10.82 (6.35–18.43)* | 32 (43.8%) | 13.48 (7.80–23.28)* | | Atrial fibrillation () | 13 (21.3%) | 2.82 (1.46–5.42)* | 12 (19.7%) | 2.96 (1.50–5.83)* | | Obesity () | 14 (17.9%) | 2.26 (1.21–4.21)* | 13 (16.7%) | 2.40 (1.26–4.58)* |
| | Platelets at the time of diagnosis () | | 1.01 (1.00–1.01)* | | 1.01 (1.00–1.01)* | | PLT > 299.5 | 68 (15.5%) | 3.89 (2.38–6.36)* | — | — | | PLT > 330.5 | — | — | 54 (14.6%) | 3.66 (2.25–5.96)* | | WBC () | | 0.92 (0.86–0.99)* | | 0.93 (0.86–0.99)* | | WBC < 6.36 | 51 (12.9%) | 1.92 (1.24–2.97)* | 43 (10.9%) | 1.72 (1.09–2.72)* | | Hemoglobin () | | 0.99 (0.98–1.00) | | 0.99 (0.98–1.00) | | Hemoglobin < 123.5 | 53 (10.3%) | 1.20 (0.78–1.87) | 46 (8.9%) | 1.16 (0.73–1.85) | | PT () | | 0.96 (0.49–1.86) | | 0.89 (0.43–1.83) | | PT < 1.05 | 48 (9.8%) | 1.10 (0.70–1.71) | 43 (8.7%) | 1.16 (0.73–1.87) | | aPTT () | | 1.02 (0.99–1.06) | | 1.03 (0.99–1.07) | | aPTT > 35.95 | 45 (11.7%) | 1.59 (1.02–2.47)* | 41 (10.7%) | 1.74 (1.08–2.78)* | | Fibrinogen () | | 1.08 (0.90–1.28) | | 1.09 (0.91–1.31) | | Fibrinogen > 3.15 | 47 (11.2%) | 1.52 (0.96–2.41) | — | — | | Fibrinogen > 3.35 | — | — | 37 (10.0%) | 1.48 (0.91–2.40) | | D dimers () | | 0.97 (0.82–1.15) | | 0.97 (0.81–1.17) | | D dimers > 0.40 | 32 (11.9%) | 1.65 (1.01–2.69)* | — | — | | D dimers > 0.38 | — | — | 31 (9.2%) | 1.41 (0.84–2.36) |
|
|
Logistical regression.
Statistically significant value OR ().
|
